Cure My Disease

Don't miss your cure!

 Log in / Sign up

Support program aims to ease side effects of thyroid cancer drug

NCT ID NCT01298323

Completed Symptom relief Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Apr 20, 2026 · Last updated May 14, 2026 · Updated 7 times

Summary

This study looked at whether a patient outreach program could help people with advanced medullary thyroid cancer spend less time dealing with moderate-to-severe side effects from the drug vandetanib. About 205 adults took part. The goal was to see if extra support and monitoring during the first year of treatment could improve how patients feel.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Faculdade de Medicina de Ribeirao Preto - USP Site Number : 702

    Ribeirão Preto, São Paulo, 14048-900, Brazil

  • Hospital De Clinicas De Porto Alegre Site Number : 701

    Porto Alegre, Rio Grande do Sul, 90035-003, Brazil

  • Investigational Site Number 1001

    London, N6A 4L6, Canada

  • Investigational Site Number 1002

    Sherbrooke, J1H 5N4, Canada

  • Investigational Site Number 1003

    Toronto, M5G2M9, Canada

  • Investigational Site Number 1301

    Beijing, 100021, China

  • Investigational Site Number 1302

    Shanghai, China

  • Investigational Site Number 1901

    Prague, 15006, Czechia

  • Investigational Site Number 2001

    Odense C, 5000, Denmark

  • Investigational Site Number 2201

    Helsinki, FI-00029, Finland

  • Investigational Site Number 2601

    Würzburg, 97080, Germany

  • Investigational Site Number 2602

    Essen, 45122, Germany

  • Investigational Site Number 2603

    Halle, 06120, Germany

  • Investigational Site Number 2801

    Sutton, SM25PT, United Kingdom

  • Investigational Site Number 2802

    Glasgow, G120YN, United Kingdom

  • Investigational Site Number 3001

    Athens, 11528, Greece

  • Investigational Site Number 301

    St Leonards, 2065, Australia

  • Investigational Site Number 3501

    Mumbai, 400012, India

  • Investigational Site Number 3502

    Vellore, 632004, India

  • Investigational Site Number 4001

    Jerusalem, 91120, Israel

  • Investigational Site Number 401

    Vienna, 1901, Austria

  • Investigational Site Number 4101

    Pisa, 56124, Italy

  • Investigational Site Number 4102

    Roma, 00161, Italy

  • Investigational Site Number 4104

    Naples, Italy

  • Investigational Site Number 501

    Brussels, 1000, Belgium

  • Investigational Site Number 5702

    Poznan, 60-355, Poland

  • Investigational Site Number 5703

    Warsaw, 02-781, Poland

  • Investigational Site Number 6001

    Seoul, South Korea

  • Investigational Site Number 6201

    Moscow, 115478, Russia

  • Investigational Site Number 6202

    Obninsk, 249036, Russia

  • Investigational Site Number 6203

    Saint Petersburg, 197022, Russia

  • Investigational Site Number 6204

    Moscow, 125284, Russia

  • Investigational Site Number 701

    Porto Alegre, 90035-003, Brazil

  • Investigational Site Number 702

    Ribeirão Preto, 14048-900, Brazil

  • Investigational Site Number 7201

    Uppsala, 75185, Sweden

  • Investigational Site Number 901

    Sofia, 1527, Bulgaria

  • Investigational Site Number : 1001

    London, Ontario, N6A 4L6, Canada

  • Investigational Site Number : 1002

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Investigational Site Number : 1003

    Toronto, Ontario, M5G2M9, Canada

  • Investigational Site Number : 1301

    Beijing, 100021, China

  • Investigational Site Number : 1302

    Shanghai, China

  • Investigational Site Number : 1901

    Prague, 15006, Czechia

  • Investigational Site Number : 2001

    Odense C, 5000, Denmark

  • Investigational Site Number : 2201

    Helsinki, FI-00029, Finland

  • Investigational Site Number : 2601

    Würzburg, 97080, Germany

  • Investigational Site Number : 2602

    Essen, 45122, Germany

  • Investigational Site Number : 2603

    Halle, 06120, Germany

  • Investigational Site Number : 2801

    Sutton, Surrey, SM25PT, United Kingdom

  • Investigational Site Number : 2802

    Glasgow, G120YN, United Kingdom

  • Investigational Site Number : 3001

    Athens, 11528, Greece

  • Investigational Site Number : 301

    St Leonards, New South Wales, 2065, Australia

  • Investigational Site Number : 3501

    Mumbai, 400012, India

  • Investigational Site Number : 3502

    Vellore, 632004, India

  • Investigational Site Number : 4001

    Jerusalem, 91120, Israel

  • Investigational Site Number : 401

    Vienna, 1901, Austria

  • Investigational Site Number : 4101

    Pisa, 56124, Italy

  • Investigational Site Number : 4102

    Roma, 00161, Italy

  • Investigational Site Number : 4104

    Naples, Italy

  • Investigational Site Number : 501

    Anderlecht, 1070, Belgium

  • Investigational Site Number : 5702

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Investigational Site Number : 5703

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Investigational Site Number : 6001

    Seoul, 03080, South Korea

  • Investigational Site Number : 6201

    Moscow, 115478, Russia

  • Investigational Site Number : 6202

    Obninsk, 249036, Russia

  • Investigational Site Number : 7201

    Uppsala, 75185, Sweden

  • Investigational Site Number : 901

    Sofia, 1527, Bulgaria

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER MEDULLARY THYROID CANCER